BioCentury
ARTICLE | Finance

Centocor Inc.

December 18, 1995 8:00 AM UTC

Centocor Inc. last week halted its EPILOG trial of ReoPro in a Phase III all comers trial in angioplasty after an interim look revealed overwhelmingly positive data. (see BioCentury Extra, Dec. 15)....